PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review

Cook, Sara; Tinker, Anna V.

doi:10.1007/s40259-019-00347-4

Cited by 39 publications

(32 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Poly(ADP-ribose) polymerase (PARP) inhibitors are approved for use in BRCA1 and BRCA2 (BRCA)-mutant breast and ovarian cancers (1,2), and have also shown evidence of activity in patients with BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC), based on a well-described synthetically lethal effect (3).…”

Section: Introductionmentioning

confidence: 99%

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

Abida

Campbell

Patnaik

et al. 2020

Clinical Cancer Research

306

261

View full text Add to dashboard Cite

Association for Cancer Research. D. Campbell has nothing to disclose. A. Patnaik has served in a consulting or advisory role for Exelixis, Janssen, and Jounce Therapeutics; has received honoraria from Clovis Oncology, Merck, Prime Inc, and Roche; and has received research funding from Clovis Oncology, Bristol-Myers Squibb, and GlaxoSmithKline. J. Shapiro has served in a consulting or advisory role for Amgen, Astellas, Ipsen, Merck, and Roche and received financial support for travel from Amgen and Merck. B. Sautois has served a consulting or advisory role for Clovis Oncology, Astellas, Janssen, and Sanofi and received financial support for travel and/or accommodation from Janssen. N.J. Vogelzang has served in a consulting or advisory role for Clovis Oncology,

show abstract

Section: Introductionmentioning

confidence: 99%

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

Abida

Campbell

Patnaik

et al. 2020

Clinical Cancer Research

306

261

View full text Add to dashboard Cite

show abstract

“…(PARPi), and immune checkpoint inhibitors, have shown good performance in delaying recurrence and prolonging the overall survival time of patients. For example, ovarian cancer patients with BRCA1/2 mutations treated with PARPi therapy showed an ∼4-fold longer progression-free survival compared with those taking the placebo, whereas the increase for patients without the BRCA1/2 mutation was ∼2-fold (90). However, the use of PARPi may not avoid developing drug resistance, and more effective targeted therapies are required to prevent drug resistance.…”

Section: The Microbiome In Cancer Treatmentmentioning

confidence: 99%

Opportunities and Challenges of the Human Microbiome in Ovarian Cancer

et al. 2020

View full text Add to dashboard Cite

Ovarian cancer is the most lethal malignancy among gynecological cancers worldwide. Most ovarian cancer patients are diagnosed at an advanced stage because of non-specific clinical symptoms. The human microbiome plays a crucial role in maintaining the normal physiological and pathological state of the body. With the development of technologies such as DNA and 16S rRNA sequencing, an increasing number of findings on the role of microbiome in cancers are being reported. Microbiome abnormalities are increasingly associated with diseases, including cancer development, and response to therapies. Some studies have shown the relationship between microbiome changes and ovarian cancer. However, the mechanisms underlying this relationship are not yet fully understood. Here, we summarize the key findings in this regard by focusing on estrogen metabolism and host recognition receptors in microorganisms and changes in the gut or pelvic microbiome in patients with ovarian cancer. We further discuss the potential of using the microbiome as a novel biomarker for cancers. We also highlight the possibility to use microorganisms as a treatment modality to enhance the immune system, activate anti-tumor response, mediate chemotherapy resistance, and ameliorate the adverse effects of the treatment.

show abstract

“…Neoadjuvant chemotherapy (NACT) followed by debulking surgery has been shown to have similar progression‐free survival (PFS) and overall survival (OS) as upfront debulking surgery in HGSC . With the availability of new treatment options such as anti‐angiogenic agents, polyadenosine diphosphate‐ribose polymerase (PARP) inhibitors, hormone receptor modulators, immune check‐point inhibitors and therapeutic vaccines, it is increasingly important to make an early prediction of tumour response to NACT.…”

Section: Crs In High Grade Serous Tubo‐ovarian Carcinoma (Hgsc)mentioning

confidence: 99%

Role of the pathologist in assessing response to treatment of ovarian and endometrial cancers

Williams

Ganesan

2019

Histopathology

View full text Add to dashboard Cite

Standardisation of pathological evaluation of tissue responses to therapy permits robust stratification of patient outcomes for management decisions and allows comparison of results across clinical trials. In gynaecological pathology there are two major areas where pathological assessment of treatment response is currently used to determine ongoing therapy. High‐grade serous carcinoma (HGSC) of tubo‐ovarian origin frequently presents as high‐stage disease and may be managed by neoadjuvant chemotherapy with debulking surgery. The chemotherapy response score (CRS) is a reproducible, validated three‐tiered morphological scoring system to assess the response of HGSC to treatment. Interobserver agreement is shown to be substantial following online training, and women with CRS3 have significantly improved progression‐free and overall survival. Low‐grade endometrioid endometrial cancer and atypical hyperplasia/endometrioid intraepithelial neoplasia may be managed by progestogenic therapy in women who wish to preserve fertility or for whom medical co‐morbidities preclude surgical management. The response to treatment is assessed histologically in successive endometrial biopsies. The histological parameters are well described, but the pathological classification of treatment response is still under development. Pathological assessment of the response to treatment is incorporated into clinical guidelines.

show abstract

PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review

Cited by 39 publications

References 67 publications

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

Opportunities and Challenges of the Human Microbiome in Ovarian Cancer

Role of the pathologist in assessing response to treatment of ovarian and endometrial cancers

Contact Info

Product

Resources

About